|
|
|
|
Vol. 59, Issue 5, 1171-1180, May 2001
Department of Pharmacology and Toxicology (E.M.L., C.J.O., S.P.C.C.) and the Cancer Research Laboratories (E.M.L., Q.M., C.J.O., R.G.D., S.P.C.C.), Queen's University, Kingston, Ontario, Canada
| |
Abstract |
|---|
|
|
|---|
The 190-kDa phosphoglycoprotein multidrug resistance protein 1 (MRP1)
(ABCC1) confers resistance to a broad spectrum of anticancer drugs and
also actively transports certain xenobiotics with reduced glutathione
(GSH) (cotransport) as well as conjugated organic anions such as
leukotriene C4 (LTC4). In the present study, we have investigated a series of bioflavonoids for their ability to
influence different aspects of MRP1 function. Most flavonoids inhibited
MRP1-mediated LTC4 transport in membrane vesicles and inhibition by several flavonoids was enhanced by GSH. Five of the
flavonoids were competitive inhibitors of LTC4 transport
(Ki, 2.4-21 µM) in the following rank
order of potency: kaempferol > apigenin (+ GSH) > quercetin > myricetin > naringenin (+ GSH). These
flavonoids were less effective inhibitors of 17
-estradiol 17
-(D-glucuronide) transport. Moreover, their rank order
of inhibitory potency for this substrate differed from that for
LTC4 transport inhibition but correlated with their
relative lipophilicity. Several flavonoids, especially naringenin and
apigenin, markedly stimulated GSH transport by MRP1, suggesting they
may be cotransported with this tripeptide. Quercetin inhibited the
ATPase activity of purified reconstituted MRP1 but stimulated
vanadate-induced trapping of 8-azido-
-[32P]ADP by
MRP1. In contrast, kaempferol and naringenin stimulated both MRP1
ATPase activity and trapping of ADP. In intact MRP1-overexpressing cells, quercetin reduced vincristine resistance from 8.9- to 2.2-fold, whereas kaempferol and naringenin had no effect. We conclude that dietary flavonoids may modulate the organic anion and GSH transport, ATPase, and/or drug resistance-conferring properties of MRP1. However,
the activity profile of the flavonoids tested differed from one
another, suggesting that at least some of these compounds may interact
with different sites on the MRP1 molecule.
| |
Introduction |
|---|
|
|
|---|
Resistance
to multiple anticancer drugs is a major obstacle to the successful
treatment outcome of many human malignancies. In tumor cell lines,
multidrug resistance is often associated with an ATP-dependent decrease
in cellular drug accumulation attributed to the overexpression of one
or other of the plasma membrane drug transporters: the 170-kDa
P-glycoprotein (Juliano and Ling, 1976
; Sharom, 1997
) or the 190-kDa
multidrug resistance protein 1 (MRP1) (Cole et al., 1992
; Hipfner et
al., 1999a
). Increased expression of MRP1 and P-glycoprotein has also
been reported in a variety of hematological and solid tumors,
suggesting an important clinical role for these transport proteins.
MRP1 and P-glycoprotein belong to the ATP-binding cassette (ABC)
superfamily of transport proteins but share very limited amino acid
identity (Cole et al., 1992
). Moreover, P-glycoprotein (ABCB1) has a
four domain structure typical of most ABC transporters with two
nucleotide binding domains (NBDs) each preceded by a hydrophobic
membrane spanning domain. In contrast, MRP1 (ABCC1) has a five domain
structure with a third NH2-proximal membrane spanning domain with five transmembrane segments and an extracytosolic NH2 terminus (Cole et al., 1992
; Bakos et al.,
1996
; Hipfner et al., 1997
, 1999a
). Nevertheless, despite these
structural differences, both proteins confer resistance to a similar
spectrum of natural product type drugs as well as the folic acid
antimetabolite methotrexate (Cole et al., 1994
; Hipfner et al., 1999a
;
Hooijberg et al., 1999a
). On the other hand, only MRP1 is an active
ATP-dependent transporter of various conjugated organic anions and its
substrates range from potential physiological substrates such as the
cysteinyl leukotriene LTC4, and 17
-estradiol
17-(
-D-glucuronide) (E217
G), to
substrates of toxicological relevance such as the exo and
endo GSH conjugates of the mycotoxin aflatoxin
B1 (Hipfner et al., 1999a
). The mechanisms by
which MRP1 and P-glycoprotein transport unconjugated xenobiotics and
thereby decrease cellular drug accumulation in human tumor cells are
very different. P-glycoprotein has been shown to directly bind and
transport drugs to which it confers resistance, whereas MRP1 does not
(Loe et al., 1996
; Sharom, 1997
). Instead, MRP1 seems to efflux some
xenobiotics (e.g., vincristine, daunorubicin) through a cotransport
mechanism with reduced glutathione (GSH) (Loe et al., 1998
; Rappa et
al., 1999
; Renes et al., 1999
). In addition to enhancing direct
transport of some MRP1 substrates, GSH has been shown to increase the
potency of certain compounds to inhibit conjugated organic anion
transport activity by MRP1. For example, transport of
LTC4 is poorly inhibited by vincristine or
verapamil alone but in the presence of GSH, inhibition by these drugs
is enhanced more than 20-fold (Loe et al., 1996
, 1998
, 2000
).
The flavonoids are a large group of polyphenolic antioxidants found in
vegetables, fruits, and beverages such as tea and wine. In addition to
their well known antioxidant effects, flavonoids have a broad range of
biological activities that includes inhibition of tyrosine kinases and
serine/threonine kinases (Akiyama et al., 1987
), topoisomerase II
(Yamashita et al., 1990
), and the drug-metabolizing cytochromes P450
1A1/2 (Edenharder et al., 1997
), as well as activation of p53 (Plaumann
et al., 1996
) and the cystic fibrosis transmembrane conductance
regulator (CFTR) chloride channel (Illek et al., 1999
). Furthermore,
flavopiridol, a synthetic flavone currently in phase I clinical trials
as an antineoplastic agent, has been shown to be a potent inhibitor of
several cyclin-dependent kinases, including CDK2 and CDK4 (Carlson et
al., 1996
). Natural flavonoids are abundant in a normal diet and are
also available commercially, marketed as antioxidant tablets.
Flavonoids are generally thought to have many beneficial health
effects, including antiproliferative and anticarcinogenic effects (Le
Marchand et al., 2000
) but recently, it has been suggested that
maternal ingestion of these compounds may contribute to infant leukemia
through a mechanism proposed to involve topoisomerase II (Strick et
al., 2000
).
Mega-dose quantities of certain flavonoids are frequently ingested by healthy individuals as antioxidant supplements and by cancer patients as a form of alternative or complementary therapy. Consequently, it is important to know whether these compounds affect the function of proteins involved in drug metabolism and/or transport because this may have a significant impact on the physiological functions carried out by these proteins and possibly, the pharmacokinetics and thus efficacy of chemotherapy. In the present study, we have investigated several bioflavonoids for their ability to modulate the transport, ATPase, and drug resistance-conferring activities of MRP1. We found that the effects of flavonoids on these activities were variable, and that the ability of a flavonoid to modulate one activity of MRP1 was not necessarily linked to its ability to modulate another activity of the protein. Our results also indicate that the flavonoids should be considered individually rather than as a class of compounds with respect to their interactions with MRP1 and probably with other related ABC proteins.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials and Cell Lines.
[14,15,19,20-3H]LTC4
(115.3 Ci/mmol),
[6,7-3H]E217
G (55 Ci/mmol), and [glycine 2-3H]GSH (50 Ci/mmol)
were purchased from PerkinElmer Life Science Products (Guelph, ON,
Canada), and 8-azido-
-[32P]ATP (20 Ci/mmol)
was from ICN Biomedicals (Irvine, CA). LTC4 was
obtained from Calbiochem (San Diego, CA), and DTT and 2-mercaptoethanol from ICN (Aurora, OH). ATP, AMP, E217
G, GSH,
GSSG, sodium orthovanadate, ouabain, vincristine, genistin, genistein,
naringin, naringenin, quercetin, kaempferol, apigenin, and myricetin
were from Sigma Chemical (Oakville, ON, Canada). Creatine kinase and
creatine phosphate were from Roche Molecular Biochemicals (Laval, PQ,
Canada). The HeLa cell line T5 is stably transfected with a pRc/CMV
vector containing the complete coding sequence of MRP1 and has been
described previously (Cole et al., 1994
; Grant et al.,
1994
). The C1 HeLa cell line is stably transfected with the
pRc/CMV vector alone. HeLa cells were maintained in RPMI 1640 medium
supplemented with 4 mM L-glutamine and 5%
defined bovine calf serum and 400 µg/ml geneticin (G418) (Life
Technologies, Burlington, ON, Canada).
High-Performance Liquid Chromatography (HPLC) Analysis of
Flavonoids.
To determine the relative hydrophilicity of the
flavonoids, HPLC was carried out using a Waters 717 HPLC system
equipped with a multisolvent delivery system and dual wavelength
absorbance detector based on a method described by Oliveira and Watson
(2000)
. Flavonoids were prepared at a concentration of 500 µM in DMSO and 10 µl was injected onto a 3.9 × 150-mm Nova Pak C18 column (Waters, Mississauga, ON, Canada). The isocratic mobile phase consisted
of 0.1% trifluoroacetic acid and methanol (6:4, v/v) and was used with
a flow rate of 1 ml/min. Absorbance was measured at 254 nm and peaks
were analyzed using Waters Millenium 32 software.
Membrane Vesicle Preparation.
Plasma membrane vesicles were
prepared as described with modifications (Loe et al., 1996
). Briefly,
transfected HeLa cells were homogenized in buffer containing 250 mM
sucrose/50 mM Tris pH 7.5/0.25 mM CaCl2 and
protease inhibitor cocktail tablets (Complete, mini EDTA free) (Roche
Molecular Biochemicals, Indianapolis, IN). Cells were disrupted by
N2 cavitation (5-min equilibration at 200 psi),
and then released to atmospheric pressure and EDTA added to 1 mM. The
suspension was centrifuged at 800g at 4°C for 15 min and
the supernatant was layered onto a 10-ml 35% (w/w) sucrose/1 mM
EDTA/50 mM Tris, pH 7.4 cushion after centrifugation at
100,000g at 4°C for 1 h, the interface was removed
and placed in a 25 mM sucrose/50 mM Tris, pH 7.4 solution and
centrifuged at 100,000g at 4°C for 30 min. The membranes
were washed with buffer (250 mM sucrose, 50 mM Tris pH 7.4) and then
resuspended by vigorous syringing with a 27-gauge needle. Protein
concentration was determined using a Bradford assay (Bio-Rad,
Mississauga, ON, Canada) and aliquots of membranes were stored at
70°C. Relative levels of MRP1 protein in membrane vesicles were
determined by immunoblot analysis as before with the human
MRP1-specific monoclonal antibody QCRL-1 (Hipfner et al., 1994
).
[3H]LTC4 Transport Studies.
LTC4 transport inhibition assays were carried out
by a rapid filtration method as described previously (Loe et al.,
1996
). Assays were carried out at 23°C in a 50-µl volume containing
vesicle protein (2 µg), ATP, or AMP (4 mM),
MgCl2 (10 mM), GSH (0, 1 or 3 mM), DTT (10 mM),
creatine phosphate (10 mM), creatine kinase (100 µg/ml),
[3H]LTC4 (50 nM; 40 nCi),
and flavonoid dissolved in DMSO (0.7%). After incubations for 60 s, the entire reaction mixture was removed and added to 800 µl of
ice-cold Tris sucrose buffer. The solution was then filtered through
glass fiber filters (type A/E), washed twice with Tris sucrose buffer,
and radioactivity quantitated by liquid scintillation counting.
Transport in the presence of AMP was subtracted from transport in the
presence of ATP and reported as ATP-dependent
[3H]LTC4 uptake. Results
are expressed as percentage of control (ATP-dependent
[3H]LTC4 transport with
vehicle alone) and all compounds were tested in at least three
independent experiments.
[3H]E217
G Transport Studies.
T5
membrane vesicles (8-10 µg of protein) were incubated at 37°C for
90 s in a total reaction volume of 50 µl containing
[3H]E217
G (400 nM, 40 nCi), DTT (10 mM), GSH (±3 mM), and components as described above for
LTC4 transport. Flavonoids were added at a final
DMSO concentration of
1%.
[3H]GSH Transport Studies.
ATP-dependent
transport of [3H]GSH into membrane vesicles was
measured as described above in a total reaction volume of 60 µl
containing 100 µM [3H]GSH (120 nCi/reaction)
and DTT (10 mM). To minimize GSH catabolism by
-glutamyl
transpeptidase during transport, membranes (20 µg/reaction) were
preincubated with 500 µM acivicin at 37°C for 10 min (Loe et al.,
1998
). Uptake assays were carried out for 20 min at 37°C in the
presence of verapamil (VRP) (100 µM), previously demonstrated to
stimulate MRP1-specific GSH transport (Loe et al., 2000
), or flavonoid
(30 µM) dissolved in DMSO (final concentration 0.7%). [3H]GSH uptake was also measured with membrane
vesicles prepared from control transfected C1 cells.
ATPase Activity of Purified Reconstituted MRP1.
To measure
the effect of quercetin, kaempferol, and naringenin (± GSH) on the
ATPase activity of MRP1, MRP1 was immunoaffinity purified from
drug-resistant H69AR lung cancer cells and reconstituted as described
previously (Mao et al., 1999
) with modifications (Mao et al., 2000
).
Purified reconstituted MRP1 (1 µg) was incubated at 37°C in 0.1 ml
of buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM
MgCl2, 2.5 mM ATP, and flavonoids (10 and 50 µM) dissolved in DMSO for 4 h. The effect of naringenin was
measured in the presence of 3 mM GSH and 3 mM DTT. As a positive
control, proteoliposomes were incubated with GSSG (500 µM), a known
stimulator of MRP1 ATPase activity (Chang et al., 1997
; Mao et al.,
1999
). After terminating the reactions, the amount of inorganic
phosphate released was determined immediately as described previously
(Mao et al., 1999
). The final concentration of DMSO in the reactions
was 5%, which was determined to have no significant effect on MRP1
ATPase activity.
Orthovanadate-Induced Trapping of
8-Azido-
-[32P]ADP by MRP1.
Sodium orthovanadate
(10 mM) was prepared in Tris sucrose buffer (50 mM Tris, 250 mM
sucrose, pH 7.5) and the pH adjusted to 7.5. This solution was boiled
for approximately 10 min until its yellow color disappeared and then
stored at 4°C until use. MRP1-enriched membrane vesicles (20 µg)
were incubated in Tris sucrose buffer containing
MgCl2 (5 mM), sodium orthovanadate (1 mM),
8-azido-
-[32P]ATP (5 µM, 2 µCi), EGTA
(0.1 mM), ouabain (1 mM), and sodium azide (0.02% w/v) for 15 min at
37°C, in the presence of flavonoid (50 µM) (5% v/v DMSO) and
freshly prepared GSH (3 mM) as indicated. Preliminary experiments
showed that DMSO had little or no effect on vanadate-induced trapping.
Trapping in the presence of LTC4 (1 µM) was
included as a positive control and membrane vesicles prepared from
empty vector transfected C1 HeLa cells were included as a negative
control. Reactions were terminated by the addition of 500 µl of
ice-cold Tris-EGTA buffer (50 mM Tris HCl, pH 7.4, 0.1 mM EGTA, 5 mM
MgCl2) and then centrifuged at 21,000g
for 15 min at 4°C. Resuspended membrane proteins were washed once
with 500 µl of Tris-EGTA buffer, centrifuged, and resuspended in 20 µl of the same buffer. Samples were then transferred to an open, flexible 96-well plate and exposed to UV light at 302 nm for 8 min at a
distance of 8 cm. After addition of Laemmli buffer, samples were
transferred to Microfuge tubes, vortexed, and centrifuged at
21,000g for 5 min at 4°C. The supernatants were subjected
to electrophoresis on a 10% SDS-polyacrylamide running gel. After drying, 32P-labeled proteins in the gel were
detected using a STORM 800 PhosphorImager and quantitated using
ImageQuaNT software (Molecular Dynamics, Sunnyvale, CA). Two
independent experiments were carried out and modulation of
orthovanadate-induced trapping of
8-azido-
-[32P]ADP was expressed as a mean
value relative to the DMSO control.
Chemosensitivity Testing.
The effect of quercetin,
naringenin, and kaempferol on the sensitivity of the MRP1-transfected
HeLa T5 cells to vincristine was determined using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide microtiter
plate assay as described previously (Cole et al., 1994
). Dose-response
curves were first obtained for quercetin, naringenin, and kaempferol
alone, and these compounds were then tested at a concentration (10 µM) that produced <10% cytotoxicity in combination with several
concentrations of vincristine. Within each experiment, determinations
were carried out in quadruplicate. Relative resistance factors were
calculated as the ratio of the IC50 value of the
MRP1-transfected T5 cells to the IC50 value of
the C1 cells transfected with empty pRc/CMV vector alone.
| |
Results |
|---|
|
|
|---|
HPLC Analysis and Hydrophilicity of Flavonoids.
The
bioflavonoids examined in the present study were analyzed by HPLC to
provide an estimate of their relative hydrophilicity. Their retention
times on a reverse phase column are shown in Fig. 1 and their structures are illustrated in
Fig. 2. The glycosides naringin and
genistin with retention times of <4 min were the most hydrophilic
compounds, presumably due to their attached sugar groups. Myricetin, a
flavon-3-ol with six hydroxyl groups, had the next shortest retention
time (5 min) followed by quercetin (10.2 min), another flavon-3-ol with
five hydroxyl groups. The flavanone naringenin and the isoflavone
genistein (each with three hydroxyl groups) were relatively lipophilic
with retention times of 10.9 and 15 min, respectively. Kaempferol (a
flavon-3-ol with four hydroxyl groups) and apigenin (a flavone with
three hydroxyl groups) were the most lipophilic compounds with
retention times of 20 and 23 min, respectively.
|
|
Inhibition of LTC4 Transport Activity by Bioflavonoids. ATP-dependent LTC4 uptake by MRP1-enriched T5 membrane vesicles was measured at several different concentrations of flavonoid in the presence and absence of GSH (Fig. 2). In the absence of GSH, the aglycosides genistein and naringenin were relatively weak inhibitors of LTC4 uptake (IC50 values >100 and 66 µM) (Fig. 2, A and C) and their glycoside counterparts, genistin and naringin, were even less potent (IC50 values >200 µM) (Fig. 2, B and D). GSH enhanced inhibition of LTC4 transport by genistein and naringenin by 2- and 7-fold (IC50 values of 65 and 9.5 µM, respectively, with 3 mM GSH), but had little effect on the corresponding glycosides genistin and naringin (IC50 values >200 and 98 µM, respectively, with 3 mM GSH). The flavone apigenin was a potent inhibitor of LTC4 transport (IC50, 25 µM) and inhibition by this compound was enhanced approximately 3.4-fold by GSH (IC50, 7.4 µM) (Fig. 2E). Alone, the flavon-3-ols myricetin, quercetin, and kaempferol were even more potent inhibitors of LTC4 transport (IC50 values, 7-12 µM) than apigenin but the addition of GSH had little effect on these compounds (Fig. 2, F-H).
Determination of Ki Values for Selected
Flavonoids.
Those flavonoids found to be relatively potent
inhibitors of LTC4 transport [kaempferol,
quercetin, myricetin, apigenin (+ GSH), and naringenin (+ GSH)] were
further characterized by determining the mode of inhibition (Fig.
3). Lineweaver-Burk plots showed that
kaempferol (Fig. 3A), quercetin (Fig. 3B), apigenin (+ GSH) (Fig. 3C),
naringenin (+ GSH) (Fig. 3D), and myricetin (Fig. 3E) behaved as
competitive inhibitors of MRP1-mediated LTC4
transport. The Ki values for these
compounds are summarized in Table 1 and range from 2.4 ± 1.6 µM for kaempferol to 20.8 ± 6.4 µM
for naringenin in the presence of 3 mM GSH. Their rank order for
potency of LTC4 transport inhibition was
kaempferol > apigenin (+ GSH) > quercetin > myricetin > naringenin (+ GSH), which correlated poorly with the
relative lipophilicity of these compounds as inferred from their HPLC
retention times.
|
|
Inhibition of [3H]E217
G Transport by
Bioflavonoids
The same five flavonoid inhibitors
of LTC4 transport [kaempferol, quercetin, myricetin,
apigenin (+ GSH), and naringenin (+ GSH)] were also tested for their
ability to inhibit [3H]E217
G uptake by
MRP1-enriched membrane vesicles (Fig.
4A). Overall, these compounds were less
potent with respect to inhibition of E217
G transport
than observed with LTC4 as a substrate. For example, 60 µM myricetin did not inhibit [3H]E217
G
uptake, and quercetin caused only 30% inhibition at this concentration, whereas LTC4 transport was inhibited more
than 90% at the same concentrations of these flavonoids. Kaempferol was also a less potent inhibitor of E217
G transport (40 and 70% inhibition at 10 and 30 µM, respectively) compared with its
effect on LTC4 transport (50 and 90% inhibition at 10 and
30 µM, respectively) as was apigenin (+ 3 mM GSH)
(E217
G transport was inhibited 55 and 80%, whereas
LTC4 transport was inhibited 70 and 90% at 10 and 30 µM,
respectively). In contrast, naringenin (+ GSH) inhibited E217
G and LTC4 transport with a comparable
potency (approximately 50 and 60% inhibition at 10 and 30 µM,
respectively). Thus, the rank order of potency for E217
G
transport inhibition by these flavonoids was apigenin (+ GSH) > kaempferol > naringenin (+ GSH) > quercetin
myricetin.
In contrast to the inhibition of LTC4 transport, this rank
order potency is in very good agreement with the relative lipophilicity
of these compounds, as indicated by their HPLC retention times.
|
Stimulation of [3H]GSH Transport by
Bioflavonoids
Kaempferol, quercetin, myricetin,
apigenin, and naringenin were tested at a concentration of 30 µM for
their ability to stimulate transport of [3H]GSH (Fig.
4B). VRP (100 µM) was included as a positive control and stimulated
transport 4-fold, consistent with our previous results (Loe et al.,
2000
). Kaempferol had no effect on [3H]GSH transport,
whereas myricetin and quercetin caused a moderate stimulation of
transport (1.4- and 1.7-fold, respectively). Apigenin and naringenin
strongly stimulated GSH uptake of GSH by 4.3- and 2.3-fold,
respectively. Thus, apigenin at 30 µM stimulated GSH uptake to the
same degree as 100 µM VRP. The rank order of stimulation of GSH
transport by the flavonoids was apigenin > naringenin > quercetin > myricetin > kaempferol, which did not correlate
with their rank order of either LTC4 or
E217
G transport inhibition, nor with their relative
lipophilicity as inferred from their HPLC retention times.
Effect of Flavonoids on the ATPase Activity of Purified
Reconstituted MRP1.
As two of the most abundant dietary flavonoids
and potent inhibitors of MRP1-mediated LTC4
transport, the flavon-3-ols kaempferol and quercetin were investigated
for their ability to modulate the ATPase activity of purified
reconstituted MRP1. The flavanone naringenin was also examined. We have
shown previously that H69AR cells from which MRP1 was originally cloned
express approximately 8-fold more MRP1 than the transfected HeLa T5
cells and thus, for practical reasons, the protein was purified from
H69AR cells. Quercetin inhibited MRP1 ATPase activity by 22 and 37% at
10 and 50 µM, respectively (Table 2).
In contrast, kaempferol and naringenin at 50 µM both stimulated MRP1
ATPase activity by 9%, whereas a lower concentration of these
compounds (10 µM) had no effect. GSH (3 mM) by itself had no effect
on basal ATPase activity of purified MRP1 as reported previously by us
(Mao et al., 1999
), in contrast to observations by other laboratories
that reported stimulation by this tripeptide (Chang et al., 1997
;
Hooijberg et al., 2000
). On the other hand, GSH increased stimulation
by 50 µM naringenin to 116% of control values. Finally, GSSG (500 µM) stimulated basal ATPase activity of purified MRP1 by
approximately 20%, consistent with previous findings (Chang et al.,
1997
; Mao et al., 1999
).
|
Effect of Flavonoids on Orthovanadate-Induced Trapping of
8-Azido-
-[32P]ADP by MRP1.
We and others have
previously shown that vanadate-induced trapping of
8-azido-
-[32P]ADP by MRP1 can be stimulated
by LTC4 (Bakos et al., 2000
; Gao et al., 2000
).
To examine whether flavonoids might have a similar effect, the ability
of quercetin, kaempferol, and naringenin (± GSH) to stimulate
orthovanadate-induced trapping of
8-azido-
-[32P]ADP by MRP1 was investigated.
In agreement with our previous studies in MRP1-enriched insect cell
membranes (Gao et al., 2000
), LTC4 (1 µM)
stimulated the vanadate-induced trapping of
8-azido-
-[32P]ADP by MRP1 in T5 membrane
vesicles by 1.4-fold compared with vehicle control (Fig.
5). Quercetin (50 µM) stimulated
labeling to an even greater extent than LTC4
(approximately 2-fold), whereas kaempferol (50 µM) stimulated
trapping by approximately 1.2-fold. When tested alone, naringenin also
stimulated vanadate-induced trapping approximately 1.2-fold. In
contrast, naringenin in the presence of 3 mM GSH inhibited trapping by
approximately 25%. However, this inhibition appears attributable to
GSH rather than the naringenin, because vanadate-induced trapping was
decreased by approximately 50% by 3 mM GSH alone.
|
-[32P]ADP trapping contrasts with
the findings of other investigators who reported an increase in
trapping with this tripeptide (Taguchi et al., 1997Effect of Kaempferol, Naringenin, and Quercetin on Vincristine
Sensitivity of Transfected HeLa Cells.
Kaempferol, quercetin, and
naringenin were tested for their ability to sensitize intact
MRP1-transfected HeLa T5 cells to the cytotoxic effects of vincristine.
In initial experiments with the flavonoids alone, it was noted that the
T5 cells were not resistant to these compounds relative to control C1
cells, consistent with the reports of others (Hooijberg et al., 1999b
).
Moreover, the IC10 for kaempferol, naringenin, or
quercetin was approximately 10 µM and consequently, this
concentration of bioflavonoid was used in subsequent combination
experiments with vincristine. Neither kaempferol nor naringenin had any
effect on the vincristine sensitivity of the MRP1 T5 cells or the
control C1 cells (Fig. 6, A and B). In
contrast, quercetin (10 µM) decreased the relative resistance of T5
cells to vincristine from 8.9- to 2.2-fold (Fig. 6C). None of the
bioflavonoids at a concentration of 10 µM had statistically significant effect on the vincristine sensitivity of the control transfected C1 cells.
|
| |
Discussion |
|---|
|
|
|---|
In the present study, we have examined the ability of several naturally occurring flavonoids to modulate conjugated organic anion and GSH transport and ATPase activity associated with MRP1. We also investigated the effects of these compounds on MRP1-mediated vanadate-induced trapping of ADP and to a limited extent, drug resistance. For these studies, we used inside-out membrane vesicles from HeLa cells stably transfected with MRP1 cDNA, as well as native MRP1 purified to >85% homogeneity and reconstituted into phospholipid vesicles, both systems that allow any observed effects of the flavonoids to be attributed directly to the properties of MRP1.
Initially, the effect of a series of flavonoids and several glycoside
derivatives on the uptake of the well characterized MRP1-conjugated
organic anion substrate
[3H]LTC4 into inside-out
membrane vesicles was measured as an indicator of their interaction
with MRP1. The glycosylated flavonoids have been reported to have
generally lower biological activity than their aglycoside partners
(Williamson et al., 1996
; Conseil et al., 1998
). However, most
substrates and inhibitors of MRP1 are relatively hydrophilic and
consequently, it was not necessarily expected that naringin and
genistin would be poorer inhibitors of LTC4
transport than their more lipophilic aglycoside derivatives naringenin
and genistein. Thus, although the low inhibitory potency of the
glycosides we observed suggests that their interaction with MRP1 in
inside-out membrane vesicles is significantly less than the
aglycosides, it is not clear why this is so.
We and others have shown previously that the ability of certain
unconjugated xenobiotics to inhibit MRP1 transport of organic anions in
inside-out membrane vesicles is markedly enhanced by the addition of
GSH (Loe et al., 1996
, 1998
). We found that inhibition of
LTC4 transport by apigenin and naringenin was
also enhanced by GSH, whereas other flavonoids (notably the
flavon-3-ols myricetin, quercetin, and kaempferol) were relatively
potent inhibitors without the addition of this reducing tripeptide.
LTC4 transport inhibition by genistein (an
isoflavone) was enhanced by GSH, but this occurred only at high
concentrations of flavonoid that are unlikely to be biologically
relevant. The mechanism by which GSH enhances the inhibitory potency of
certain compounds on MRP1-mediated conjugated organic anion transport
appears to result from increasing their affinity for the protein (Loe
et al., 1998
, 2000
; Qian et al., 2001
). However, the structural and/or
physical properties of a molecule that determine whether its inhibitory
action on LTC4 will be increased by GSH have yet
to be well defined. In the case of the polyphenolic flavonoids, our
results indicate that again, it is not simply related to the relative
hydrophilicity of the compound as reflected by their HPLC retention times.
As mentioned above, the flavone apigenin and the flavanone naringenin
had the greatest inhibitory effect on
[3H]LTC4 transport by
MRP1 when GSH was present. These two compounds were also the most
potent stimulators of [3H]GSH transport.
Stimulation of GSH transport by the flavonoids was unexpected and may
have implications for cellular redox homeostasis. Whether these
flavonoids are cotransported with GSH as demonstrated previously for
vincristine (Loe et al., 1998
) is not known. It may be that these
compounds interact with MRP1 to stimulate
[3H]GSH transport without being transported
themselves as shown recently for verapamil (Loe et al., 2000
). The lack
of cross-resistance of the T5 cells to the flavonoids does not seem
consistent with a cotransport mechanism but direct transport studies
with the flavonoids are required before any conclusions can be drawn.
There is good evidence in other model systems, including human colonic carcinoma Caco-2 cells, that certain flavonoids and their glucoside-, glucuronide-, and sulfate-conjugated metabolites are transported by
MRP2, a highly related ABC protein with 67% amino acid similarity to
MRP1 (Walle et al., 1999
; Walgren et al., 2000
). However, despite the
similarity of their primary structures, MRP1 and MRP2 differ in a
number of important respects. For example, MRP1 is localized to
basolateral membranes, whereas MRP2 is localized on apical membranes of
polarized cells, including gastrointestinal epithelia, and whereas the
two transporters have many substrates in common, their substrate
specificities are not identical. These differences are certain to have
important consequences with respect to the relative influence these two
transporters might have on the bioavailability and elimination of
dietary flavonoids.
The differences in rank order potency of flavonoid-mediated inhibition
of E217
G and LTC4
transport, and stimulation of GSH transport are of interest because
they support the idea that these organic anion substrates bind to
different or mutually exclusive sites on MRP1. This conclusion is in
agreement with our recent findings that substitution of a conserved
tryptophan residue in the last predicted transmembrane segment of MRP1
eliminates E217
G transport activity but leaves
LTC4- and verapamil-stimulated GSH transport
intact (Ito et al., 2001
).
Five of the flavonoids that inhibited MRP1-mediated
LTC4 transport at biologically relevant
concentrations were determined to be competitive inhibitors. The
Ki values of the flavonoids tested [which
included the flavon-3-ols myricetin, quercetin, and kaempferol alone as
well as the flavanone naringenin (+ GSH) and the flavone apigenin (+ GSH)] were in the low micromolar range, which is within a biologically
achievable plasma level (Manach et al., 1998
). The competitive nature
of LTC4 transport inhibition by these flavonoids
indicates that they bind to the same or mutually exclusive binding
site(s) on MRP1 as LTC4 but differences in their effects on other MRP1 activities suggest the latter possibility is more
likely. These findings also imply that LTC4
transport and associated physiological processes mediated by this
cysteinyl leukotriene might be affected in individuals who ingest
significant amounts of these flavonoids.
It has been reported that genistein, kaempferol, apigenin, and the
synthetic flavonoid flavopiridol increase daunorubicin accumulation in
a drug-selected MRP1 overexpressing lung cancer cell line exposed to a
50 µM concentration of these compounds (Hooijberg et al., 1999b
). We
were unable to achieve this high a concentration of flavonoids in our
transfected HeLa cells without significant toxicity. However, at a
5-fold lower concentration (10 µM), we found that only quercetin, but
not kaempferol or naringenin, increased vincristine cytotoxicity in the
T5 cells. Thus, although these three flavonoids are relatively good
inhibitors of organic anion transport by MRP1, they seem to be poor
candidates for reversing MRP1-mediated resistance to anticancer drugs.
The mechanistic relationship between the ATPase activity of ABC
transporters and transport of their substrates is still not fully
understood. However, it is generally assumed that the ability of a
compound to stimulate the ATPase activity of an ABC protein is a
reflection of its interaction with the protein and in the case of
P-glycoprotein, this has often been the sole criterion for concluding
that a molecule is transported by this ABC protein (Rao et al., 1994
;
Hooijberg et al., 1997
). However, there are substrates (e.g.,
vinblastine and daunorubicin) that inhibit rather than stimulate
P-glycoprotein ATPase activity (Sharom, 1997
). Moreover, verapamil is
one of the most effective stimulators of P-glycoprotein ATPase activity
and yet is poorly transported by this protein. Finally, although not
widely considered, many P-glycoprotein substrates have a biphasic
effect, stimulating ATPase activity at low concentrations and
inhibiting at high concentrations (Sharom, 1997
). At present there is
no satisfactory mechanistic explanation for these observations. In the
case of MRP1, kaempferol and naringenin stimulated its ATPase activity,
whereas quercetin was inhibitory. Inhibition of MRP1 ATPase activity by
quercetin has not been reported previously but is not completely
unexpected given that this flavon-3-ol is a well known inhibitor of the
ATPase activity of several other ABC proteins, including purified
reconstituted P-glycoprotein (Shapiro and Ling, 1997
). It has been
previously reported that other flavonoids (genistein, kaempferol,
flavopiridol, and apigenin) modestly stimulate MRP1 ATPase in membranes
prepared from a drug-selected lung cancer cell line pretreated with
various inhibitors to suppress the activity of other membrane ATPases
(Hooijberg et al., 1999b
, 1997
, 2000
). Although it is difficult to
compare these prior studies with our current data obtained using
purified reconstituted MRP1 because of methodological differences, it
is worth noting that kaempferol modestly stimulated the ATPase activity
in both systems. Nevertheless, our findings support the assertion of
Sharom (1997)
that it is not wise to presume that drug-stimulated
ATPase activity is always representative of the transport function of
an ABC transporter.
Another method commonly used to measure interaction of compounds with
ABC transporters is their ability to stimulate orthovanadate-induced nucleotide trapping (Taguchi et al., 1997
). Naringenin and kaempferol caused a significant stimulation of MRP1-mediated orthovanadate-induced trapping of ADP consistent with their ability to stimulate MRP1 ATPase
activity. On the other hand, quercetin also caused a large stimulation
of trapping by MRP1, which appears inconsistent with its inhibitory
effect on MRP1 ATPase activity. Thus, although both assays reflect ATP
binding and hydrolysis, our results indicate that the interaction of
quercetin with MRP1 differs from that of the other flavonoids.
Studies of purified recombinant polypeptides encoding the NBD2 of
murine P-glycoprotein (Conseil et al., 1998
) and the
P-glycoprotein-like Leishmania tropica transporter
(Perez-Victoria et al., 1999
) have suggested that quercetin and perhaps
other flavonoids interact with the ATP binding site and a vicinal
region of these proteins that binds certain steroids. These same
flavonoids have also been reported to interact with NBD1 of murine
P-glycoprotein by a similar mechanism but with apparently lower
affinity (Conseil et al., 1998
). The chloride channel activity of CFTR
(which is more closely related to MRP1 than P-glycoprotein) is also
stimulated by flavonoids such as genistein, kaempferol, apigenin, and
quercetin (Wang et al., 1998
; Illek et al., 1999
). Initially, it was
proposed that genistein acted in an indirect manner by inhibiting
protein tyrosine kinases (Akiyama et al., 1987
). However, more recent
evidence suggests that genistein interacts directly with NBD2 of CFTR
to prevent ATP hydrolysis, resulting in a prolonged open channel conformation of the protein (Wang et al., 1998
; Randak et al., 1999
).
In support of a direct and relatively specific interaction of
flavonoids with NBD2 of CFTR, genistein and quercetin were observed to
have no effect on the ATPase activity of a fusion protein encoding NBD1
and the regulatory R domain of this protein (Howell et al., 2000
).
Results from the present study suggest that quercetin in particular
interacts with at least one NBD of MRP1 causing a significant
stimulation of vanadate-dependent trapping and inhibition of ATPase
activity. We and others have shown that essentially all ADP trapping
occurs at NBD2 of MRP1 and thus quercetin might interact specifically
with this domain to increase the efficiency of ADP trapping (Gao et
al., 2000
; Nagata et al., 2000
). Although it remains possible that at
least some flavonoids might interact with the drug- or
substrate-binding sites found within one or more of the polytopic
membrane spanning domains of these ABC proteins, the studies described
above provide compelling evidence that NBD2 is a common site of
quercetin action.
In summary, our results indicate that dietary flavonoids have the
potential to influence the conjugated organic anion and GSH transport,
drug resistance-conferring, as well as the ATPase properties of MRP1.
However, it is clear that a flavonoid's ability to modulate one
activity is not necessarily linked to its ability to modulate another
activity of the protein. Our data also indicate that the flavonoids
should be considered individually rather than as a class of compounds,
because their effects on different MRP1 activities are variable.
Finally, our results and those of others (Hooijberg et al., 1997
,
1999b
) indicate that the flavonoids probably bind to more than one site
on MRP1 but in the case of quercetin at least, these sites may be
localized to the NBDs. We have recently reported the expression of
correctly folded soluble polypeptides corresponding to NBD1 and NBD2 of
MRP1 (Hipfner et al., 1999b
). The availability of these MRP1 domains
should facilitate future mechanistic studies of flavonoid interactions
with MRP1.
| |
Acknowledgments |
|---|
We thank Drs. Doug Loe and Mian Gao for expert advice, Kathy Sparks and Libby Eastman for excellent technical assistance, and Maureen Rogers for expert word processing and assistance with the preparation of the figures.
| |
Footnotes |
|---|
Received October 12, 2000; Accepted January 12, 2001
This work was supported by a grant (MT-10519) from the Medical Research Council of Canada. E.M.L. and C.J.O. are recipients of Medical Research Council of Canada Doctoral Awards, and E. M. L. is the past recipient of an Ontario Graduate Scholarship. R.G.D. is the Stauffer Cancer Research Professor of Queen's University and S.P.C.C. is a Senior Scientist of Cancer Care Ontario.
Send reprint requests to: Dr. Susan P. C. Cole, Cancer Research Laboratories, Room 328, Botterell Hall, Queen's University, Kingston, Ontario, Canada, K7L 3N6. E-mail: coles{at}post.queensu.ca
| |
Abbreviations |
|---|
MRP1, human multidrug resistance protein 1;
ABC, ATP-binding cassette;
NBD, nucleotide binding domain;
LTC4, leukotriene C4;
E217
G, 17
-estradiol 17-(
-D-glucuronide);
GSH, reduced
glutathione;
CFTR, cystic fibrosis transmembrane conductance regulator;
DTT, dithiothreitol;
GSSG, glutathione disulfide (oxidized glutathione);
HPLC, high-performance liquid chromatography;
DMSO, dimethyl sulfoxide;
VRP, verapamil.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Maeno, A. Nakajima, G. Conseil, A. Rothnie, R. G. Deeley, and S. P. C. Cole Molecular Basis for Reduced Estrone Sulfate Transport and Altered Modulator Sensitivity of Transmembrane Helix (TM) 6 and TM17 Mutants of Multidrug Resistance Protein 1 (ABCC1) Drug Metab. Dispos., July 1, 2009; 37(7): 1411 - 1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rothnie, G. Conseil, A. Y. T. Lau, R. G. Deeley, and S. P. C. Cole Mechanistic Differences between GSH Transport by Multidrug Resistance Protein 1 (MRP1/ABCC1) and GSH Modulation of MRP1-Mediated Transport Mol. Pharmacol., December 1, 2008; 74(6): 1630 - 1640. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Perrotton, D. Trompier, X.-B. Chang, A. Di Pietro, and H. Baubichon-Cortay (R)- and (S)-Verapamil Differentially Modulate the Multidrug-resistant Protein MRP1 J. Biol. Chem., October 26, 2007; 282(43): 31542 - 31548. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J. Letourneau, A. J. Slot, R. G. Deeley, and S. P. C. Cole Mutational Analysis of a Highly Conserved Proline Residue in MRP1, MRP2, and MRP3 Reveals a Partially Conserved Function Drug Metab. Dispos., August 1, 2007; 35(8): 1372 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ebert, A. Seidel, and A. Lampen Phytochemicals Induce Breast Cancer Resistance Protein in Caco-2 Cells and Enhance the Transport of Benzo[a]pyrene-3-sulfate Toxicol. Sci., April 1, 2007; 96(2): 227 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Gerk, W. Li, V. Megaraj, and M. Vore Human Multidrug Resistance Protein 2 Transports the Therapeutic Bile Salt Tauroursodeoxycholate J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 893 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Conseil, R. G. Deeley, and S. P. C. Cole Functional Importance of Three Basic Residues Clustered at the Cytosolic Interface of Transmembrane Helix 15 in the Multidrug and Organic Anion Transporter MRP1 (ABCC1) J. Biol. Chem., January 6, 2006; 281(1): 43 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, A. W. Wolkoff, and M. E. Morris FLAVONOIDS AS A NOVEL CLASS OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP1B1 (OATP-C) MODULATORS Drug Metab. Dispos., November 1, 2005; 33(11): 1666 - 1672. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Zern and M. L. Fernandez Cardioprotective Effects of Dietary Polyphenols J. Nutr., October 1, 2005; 135(10): 2291 - 2294. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahmed-Belkacem, A. Pozza, F. Munoz-Martinez, S. E. Bates, S. Castanys, F. Gamarro, A. Di Pietro, and J. M. Perez-Victoria Flavonoid Structure-Activity Studies Identify 6-Prenylchrysin and Tectochrysin as Potent and Specific Inhibitors of Breast Cancer Resistance Protein ABCG2 Cancer Res., June 1, 2005; 65(11): 4852 - 4860. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Trompier, X.-B. Chang, R. Barattin, A. d. M. d'Hardemare, A. Di Pietro, and H. Baubichon-Cortay Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1 Cancer Res., July 15, 2004; 64(14): 4950 - 4956. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhang, X. Yang, and M. E. Morris Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport Mol. Pharmacol., May 1, 2004; 65(5): 1208 - 1216. [Abstract] [Full Text] |
||||
![]() |
K. Koike, G. Conseil, E. M. Leslie, R. G. Deeley, and S. P. C. Cole Identification of Proline Residues in the Core Cytoplasmic and Transmembrane Regions of Multidrug Resistance Protein 1 (MRP1/ABCC1) Important for Transport Function, Substrate Specificity, and Nucleotide Interactions J. Biol. Chem., March 26, 2004; 279(13): 12325 - 12336. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Leslie, R. J. Bowers, R. G. Deeley, and S. P. C. Cole Structural Requirements for Functional Interaction of Glutathione Tripeptide Analogs with the Human Multidrug Resistance Protein 1 (MRP1) J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 643 - 653. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Oleschuk, R. G. Deeley, and S. P. C. Cole Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3 Am J Physiol Gastrointest Liver Physiol, February 1, 2003; 284(2): G280 - G289. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Leslie, R. G. Deeley, and S. P. C. Cole Bioflavonoid Stimulation of Glutathione Transport by the 190-kDa Multidrug Resistance Protein 1 (MRP1) Drug Metab. Dispos., January 1, 2003; 31(1): 11 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Koike, C. J. Oleschuk, A. Haimeur, S. L. Olsen, R. G. Deeley, and S. P. C. Cole Multiple Membrane-associated Tryptophan Residues Contribute to the Transport Activity and Substrate Specificity of the Human Multidrug Resistance Protein, MRP1 J. Biol. Chem., December 13, 2002; 277(51): 49495 - 49503. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Haimeur, R. G. Deeley, and S. P. C. Cole Charged Amino Acids in the Sixth Transmembrane Helix of Multidrug Resistance Protein 1 (MRP1/ABCC1) Are Critical Determinants of Transport Activity J. Biol. Chem., October 25, 2002; 277(44): 41326 - 41333. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Mao, W. Qiu, K. E. Weigl, P. A. Lander, L. B. Tabas, R. L. Shepard, A. H. Dantzig, R. G. Deeley, and S. P. C. Cole GSH-dependent Photolabeling of Multidrug Resistance Protein MRP1 (ABCC1) by [125I]LY475776. EVIDENCE OF A MAJOR BINDING SITE IN THE COOH-PROXIMAL MEMBRANE SPANNING DOMAIN J. Biol. Chem., August 2, 2002; 277(32): 28690 - 28699. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Loest, S. K. Noh, and S. I. Koo Green Tea Extract Inhibits the Lymphatic Absorption of Cholesterol and {alpha}-Tocopherol in Ovariectomized Rats J. Nutr., June 1, 2002; 132(6): 1282 - 1288. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-M. Qian, W. Qiu, M. Gao, C. J. Westlake, S. P. C. Cole, and R. G. Deeley Characterization of Binding of Leukotriene C4 by Human Multidrug Resistance Protein 1. EVIDENCE OF DIFFERENTIAL INTERACTIONS WITH NH2- AND COOH-PROXIMAL HALVES OF THE PROTEIN J. Biol. Chem., October 12, 2001; 276(42): 38636 - 38644. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||